No connection

Search Results

HCWB vs IMCC

HCWB
HCW Biologics Inc.
BEARISH
Price
$0.36
Market Cap
$2.5M
Sector
Healthcare
AI Confidence
98%
IMCC
IM Cannabis Corp.
BEARISH
Price
$0.36
Market Cap
$2.2M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
HCWB
--
IMCC
--
Forward P/E
HCWB
-0.66
IMCC
-0.28
P/B Ratio
HCWB
-0.45
IMCC
-0.8
P/S Ratio
HCWB
45.26
IMCC
0.04
EV/EBITDA
HCWB
-0.58
IMCC
-3.49

Profitability

Gross Margin
HCWB
20.0%
IMCC
17.7%
Operating Margin
HCWB
-18370.3%
IMCC
-31.42%
Profit Margin
HCWB
0.0%
IMCC
-20.68%
ROE
HCWB
--
IMCC
--
ROA
HCWB
-31.19%
IMCC
-10.92%

Growth

Revenue Growth
HCWB
-93.2%
IMCC
17.6%
Earnings Growth
HCWB
--
IMCC
--

Financial Health

Debt/Equity
HCWB
2.46
IMCC
--
Current Ratio
HCWB
0.11
IMCC
0.67
Quick Ratio
HCWB
0.09
IMCC
0.41

Dividends

Dividend Yield
HCWB
--
IMCC
--
Payout Ratio
HCWB
0.0%
IMCC
0.0%

AI Verdict

HCWB BEARISH

HCWB exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing a liquidity crisis with a Current Ratio of 0.11 and a catastrophic revenue collapse of -93.20% YoY. With a negative Price-to-Book ratio (-0.45) and an operating margin of -18370.31%, the firm is effectively eroding its remaining capital. The stock's 96% decline over the past year reflects a market pricing in a high probability of insolvency.

Strengths
Positive Gross Margin (20%)
Single analyst target price ($2.00) suggests theoretical upside
Recent 1-week short-term price bounce (+36%)
Risks
Extreme liquidity risk (Current Ratio 0.11)
Catastrophic revenue decline (-93.20% YoY)
Negative shareholder equity (Price/Book -0.45)
IMCC BEARISH

IMCC exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9 and the absence of a Graham Number or Altman Z-Score due to negative equity (Price/Book: -0.80). While the company has shown recent revenue growth of 17.6% and a series of EPS 'beats,' these are marginal improvements on a foundation of deep losses and negative margins. The catastrophic 5-year price decline of 99.9% and a current ratio of 0.67 indicate a high risk of insolvency and a lack of investor confidence.

Strengths
Positive YoY revenue growth of 17.60%
Recent quarterly EPS beats (3 of last 4 quarters)
Extremely low Price/Sales ratio (0.04)
Risks
Negative equity as indicated by Price/Book of -0.80
Severe liquidity risk with a Current Ratio of 0.67 and Quick Ratio of 0.41
Persistent negative operating margins (-31.42%)

Compare Another Pair

HCWB vs IMCC: Head-to-Head Comparison

This page compares HCW Biologics Inc. (HCWB) and IM Cannabis Corp. (IMCC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile